● Recruiting

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Condition: Baseline Thrombocytopenia · Sponsor: Methodist Health System

PhaseN/A

Planned participants300

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

This description comes directly from the study's public registry record.

Talk to the study team

Bethany Brauer · 214-947-4681 · mhsirb@mhd.com

Colette Ngo Ndjom · 214-947-1289 · mhsirb@mhd.com

Always discuss trial participation with your own doctor first.

Locations (1)

Methodist Dallas Medical Center

Dallas, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06223607